ProMIS Neurosciences (PMN) has raised $0.8M at-the-market from an existing healthcare focused institutional investor. The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 984,736 common shares, no par value. The Pre-Funded Warrants were sold at a price of $0.8124 per share, which represents the per share offering price for the Common Shares less a $0.0001 per share exercise price for each such Pre-Funded Warrant. The Pre-Funded Warrants will be immediately excercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The closing of the offering is expected to occur on or about July 24, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to ProMIS are expected to be approximately $0.8 million, before deducting certain offering expenses. ProMIS intends to use the net proceeds from the offering towards its further advancement of the clinical development of PMN310, its lead therapeutic candidate, as well as for working capital and other general corporate expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences Gains FDA Fast Track for PMN310
- 3 Penny Stocks to Watch Now, 7/22/25
- Buy Rating for ProMIS Neurosciences Driven by Fast Track Designation and Promising Alzheimer’s Treatment Potential
- Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today?
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!